Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | MITF | O75030 | 2/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | HTT | P42858 | 6/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RNF4 | P78317 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748680 | 0.90 | RNF4 (0.71) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL9081388 | 0.87 | NPC1 (0.76) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL11128513 | 0.86 | NPC1 (0.63) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL1031451 | 0.82 | HDAC3 (0.60) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL9250647 | 0.81 | ALDH1A1 (0.61) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL9322341 | 0.81 | NPC1 (0.58) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL8868001 | 0.81 | NPC1 (0.58) | NPC1RAB9AMITFXBP1NPSR1 | |
| SCHEMBL13652580 | 0.80 | GAA (0.59) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL7937661 | 0.80 | MEN1 (0.53) | KMT2AMAPTMEN1GAAPOLB | |
| SCHEMBL4787002 | 0.80 | KMT2A (0.51) | NPC1RAB9ASMN1; SMN2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1028962-B1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6399597-B1 | CARBAPENICILLIN ANTIBIOTICS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1028962-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6294529-B1 | ANTIBIOTICS BACTERICIDES | MERCK & CO., INC. | 2001-09-25 | — | — | US | disclosed |
| US-6140318-A | FOR TREATING BACTERIAL INFECTIONS | MERCK & CO., INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1028962-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999020628-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | NPC1 3663/4885RAB9A 2884/4885MITF 812/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | NPC1 215/4885RAB9A 2053/4885MITF 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.